States with medical marijuana laws saw 20 percent drop in some opioid prescriptions
States with active medical marijuana laws saw certain opioid prescription rates drop nearly 20 percent compared to states without medical marijuana programs, according to a first-of-its-kind study out of Columbia University’s Irving Medical Center.
Authors said the findings underscore the importance of providing patients with pain management alternatives, such as cannabis, in efforts to reduce opioid use.
Stories you may be interested in
Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders
Report of the Guideline Development Subcommittee of the American Academy of Neurology: We performed a systematic review of medical marijuana (1948–November 2013) to address treatment of symptoms of multiple sclerosis (MS), epilepsy, and movement disorders. We graded the studies according to the American Academy of Neurology classification scheme for therapeutic articles. Read the full…
Read More 
New Feature: Calendar Integration
At Arfinn Med, we’re excited to announce the third feature update to join automated text messaging and note templating: calendar integration. With this addition, physicians can now integrate their Google Calendar or Calendy account. The implementation of calendar integration rounds out the Arfinn Med portal, making it a physician’s one-stop-shop EMR tool. How It Works…
Read More 
Assessing Health-Related Outcomes of Medical Cannabis Use among Older Persons: Findings from Colorado and Illinois
ABSTRACT Objectives To assess health-related outcomes associated with medical cannabis use among older patients in Colorado and Illinois enrolled in their home state’s medical cannabis program. Methods Cross-sectional data from anonymous surveys were collected from 139 persons over the age of 60 using medical cannabis in the past year. We used structural equation modeling (SEM)…
Read More 
Survey of oncologists finds knowledge gap on medical marijuana
As more states legalize medical marijuana, two key groups — researchers whose job is it to understand its benefits and drawbacks, and physicians charged with advising potential users — are struggling to catch up with policymakers. Ilana Braun, an assistant professor of psychiatry at Harvard Medical School and chief of the division of adult psychosocial…
Read More 
Updated Arfinn Med Scheduler
As your practice begins to grow, it’s important that your booking system is able to keep up. That’s why Arfinn Med has just released, in its newest update, the multi-view scheduling and booking platform. This allows you and/or your staff the ability to customize appointment types, hours of availability, display name, and confirmation emails for…
Read More 
Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease
A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and…
Read More